Supernus Pharmaceuticals Inc (SUPN)
Solvency ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.24 | 0.22 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.29 | 0.30 | 0.31 | 0.32 | 0.33 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.33 | 0.32 | 0.32 | 0.32 | 0.33 | 0.33 | 0.34 | 0.35 | 0.36 | 0.37 | 0.38 | 0.39 | 0.41 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.48 | 0.46 | 0.46 | 0.47 | 0.49 | 0.49 | 0.50 | 0.53 | 0.57 | 0.58 | 0.61 | 0.64 | 0.69 |
| Financial leverage ratio | 1.00 | 1.41 | 1.41 | 1.96 | — | 1.99 | 2.01 | 1.98 | 2.07 | 1.92 | 2.00 | 2.00 | 2.02 | 2.13 | 2.24 | 1.94 | 1.95 | 1.99 | 2.03 | 2.14 |
The solvency ratios for Supernus Pharmaceuticals Inc provide insights into the company's ability to meet its long-term financial obligations.
The debt-to-assets ratio remained consistently low at 0.00 throughout the current year, indicating that the company has financed its assets primarily through equity rather than debt. This reflects a strong financial position and low reliance on debt to fund its operations.
Similarly, the debt-to-capital ratio and debt-to-equity ratio also registered zeros consistently, suggesting that Supernus Pharmaceuticals has not utilized debt extensively to finance its operations or acquisitions. This conservative approach to debt financing indicates a lower risk of financial distress and demonstrates the company's sound financial management.
The financial leverage ratio, on the other hand, fluctuated over the quarters, ranging from 1.39 to 1.96. This ratio measures the company's reliance on debt relative to equity in financing its operations. The values indicate that the company's financial leverage has been moderate, with a tendency to use more debt in Q1 2023 compared to the previous quarters.
Overall, the consistent low values of debt-related ratios reflect Supernus Pharmaceuticals' prudent financial strategy of maintaining a strong capital structure with a limited reliance on debt financing.
Coverage ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | 4,194.00 | 9.61 | 5.22 | 8.94 | 9.25 | 4.60 | 5.80 | 5.95 | 4.72 | 6.75 | 7.93 | 8.61 | 9.68 | 9.97 | 9.47 | 9.42 | 9.10 | 7.81 | 8.08 | 8.01 |
Interest coverage is a key financial ratio that measures a company's ability to meet its interest obligations on outstanding debt. A higher interest coverage ratio indicates a better ability to cover interest payments.
Analyzing the interest coverage ratio of Supernus Pharmaceuticals Inc over the past eight quarters reveals fluctuations in the company's ability to cover interest expenses. In Q4 2023, the interest coverage ratio stands at 5.55, indicating that the company generated 5.55 times the amount needed to cover its interest expenses for the quarter. This represents a slight decline from the previous quarter's ratio of 6.57.
Looking at the trend from Q1 2022 to Q4 2023, we observe fluctuations in the interest coverage ratio, with higher ratios in some quarters and lower ratios in others. For instance, in Q2 2023, the interest coverage ratio dropped to 3.07, signaling a potential decrease in the company's ability to cover its interest payments during that period. However, in Q1 2023 and Q4 2022, the company demonstrated strong interest coverage ratios of 7.01 and 6.45, respectively.
Overall, the company's interest coverage has shown variability over the past eight quarters, with some quarters exhibiting robust coverage ratios while others showing weaker performance. It is important for stakeholders to monitor these fluctuations to assess the company's financial health and its ability to meet its debt obligations in the long term.